Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hydromorphone PCA Intravenously vs Sustained-Release Morphine Orally in Cancer Patients With Severe Pain After Successful Titration: A Multicenter, Randomized, Controlled, Phase II Trial

NCT04243954 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT04243954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04243954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hydromorphone PCA Intravenously vs Sustained-Release Morphine Orally in Cancer Patients With Severe Pain After Successful Titration: A Multicenter, Randomized, Controlled, Phase II Trial
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 10, 2020
Completion date
November 21, 2020
Enrollment
95 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer pain